Key Highlights

  • HemoGenyx Pharmaceuticals Plc (LSE:HEMO) remains in focus in October 2026 as its lead CAR-T programme for acute myeloid leukaemia moves forward in a Phase I trial.
  • The company's half-year report, published on 28 September 2026, showed a first-half loss of about £6.56 million as clinical spending continued.
  • Early results in the first three patients showed reductions in leukaemia cells, and the company said it was ready to recruit adults at a higher dose.
  • HemoGenyx has finalised a partnership in Estonia and has been working on manufacturing transfer and trial expansion, including a paediatric amendment.
  • Funding remains a central issue for investors, with the company having raised money from institutional investors to support the programme.

Why HemoGenyx Is in Focus on 16 October 2026

HemoGenyx Pharmaceuticals Plc (LSE:HEMO), a clinical-stage biotechnology company whose shares trade on the Main Market of the London Stock Exchange, continues to draw attention from investors in mid-October 2026. No new price-sensitive statement dated Friday 16 October could be confirmed, but the stock stays on watch following its half-year report at the end of September and the steady flow of updates on its lead programme.

For a company of this size, sentiment tends to be driven by clinical news. Earlier updates showing encouraging early signals from the Phase I trial produced sharp share price moves, and investors are now waiting to see whether results at higher doses build on the initial findings. That makes every operational update, from new trial sites to patient recruitment, potentially significant for the share price.

Inside the HG-CT-1 Programme

The company's lead candidate, HG-CT-1, previously known as HEMO-CAR-T, is a chimeric antigen receptor T-cell therapy designed to treat relapsed or refractory acute myeloid leukaemia, an aggressive blood cancer with limited treatment options. The US Food and Drug Administration lifted an earlier clinical hold and consented to Phase I trials, opening the path to first-in-human testing.

In the half-year report, HemoGenyx said early data from three patients showed reductions in leukaemia cells and that it was prepared to enrol adult patients at a higher dose level. Dose escalation is a normal part of Phase I development, where the main goals are to assess safety and identify an appropriate dose, but evidence of biological activity at early stages is closely watched because it can support further investment in the programme.

The company has also filed a paediatric amendment to extend the trial to children with the disease, and it has been working on transferring manufacturing and expanding the trial footprint. A partnership in Estonia was finalised, which the company has presented as part of efforts to broaden its clinical and operational base. HemoGenyx (LSE:HEMO) has also signed a letter of intent covering a collaboration related to HG-CT-1, and it has filed its annual report to the FDA on the investigational new drug application.

Business Background

HemoGenyx Pharmaceuticals focuses on new therapies for blood diseases, including leukaemia, and on approaches intended to improve bone marrow and stem cell transplantation. Alongside its CAR-T programme, the company has worked on platform technologies aimed at conditioning patients for transplant and on immune-related research. Its strategy has been to move its lead product into the clinic as efficiently as possible while seeking partners to share the cost and risk of development.

Financial Position

Like most early-stage biotech companies, HemoGenyx has no product revenue and relies on equity funding. The first-half loss of around £6.56 million reflects ongoing clinical and research spending. The company has raised funds from institutional investors to support the trial, and it has previously issued new equity in smaller tranches. For shareholders in HemoGenyx (LSE:HEMO), the cash runway and the potential for further dilution are key considerations alongside clinical progress.

Sector and Market Context

Cell therapy remains one of the most closely watched areas of oncology. CAR-T treatments have transformed outcomes in certain lymphomas and in some forms of leukaemia, but acute myeloid leukaemia has proved harder to target because suitable antigens are often shared with healthy blood-forming cells. Any company showing a credible approach in this setting can attract significant interest, although investors generally wait for larger patient numbers before drawing firm conclusions.

Small-cap biotech shares in London have faced a tough funding environment, with investors favouring companies that have near-term clinical milestones and clear financing plans. Sentiment can shift quickly on trial updates or fundraising terms.

Risks to Consider

The risks are considerable. Phase I results from a handful of patients cannot establish efficacy, and safety issues can emerge as doses increase. CAR-T manufacturing is complex and costly, and delays in trial recruitment or regulatory processes could push back timelines. The company's dependence on equity markets means further fundraising is likely, which may dilute existing shareholders. Share price volatility is high.

What Investors Are Watching Next

Investors will be watching for confirmation that adult patients are being dosed at the higher level, any further data on leukaemia cell reductions and safety, progress on the paediatric arm, and developments with partners in Estonia and elsewhere. Clarity on funding will also be important for the outlook of HemoGenyx (LSE:HEMO).